Robert R. Redfield, MD
Professor of Medicine and Immunology and Microbiology 
Associate Director and Co-founder, Institute of Human Virology
Director of Clinical Care and Research, Institute of Human Virology
Director of Clinical Care and Research, Infectious Disease, Department of Medicine
Head, Division of Infectious Diseases

MD: Georgetown University, 1977

Phone: (410) 706-4613
Fax: (410) 706-4619
E-mail: redfield@umbi.umd.edu
Address:
Institute of Human Virology
725 West Lombard Street
Room 562 N
Baltimore, MD 21201

Clinical Research and laboratory efforts are focused on the development of biological approaches to the treatment of chronic viral pathogens with a present-day focus on HIV.  Several interrelated areas of therapeutic research are under active development:

1. the exploitation of biochemical pathways related to nucleotide biosynthesis as therapeutic targets to enhance activity of antiretroviral reverse transcriptase inhibitors;
   
   
2. assessing the role of cell cycle agents on antiviral activity of anti-retroviral drugs;
   
   
3. development and clinical evaluation of HIV specific therapeutic vaccines;
   
   
4. exploration of chemokine and chemokine receptor dynamics for therapeutic impact;
   
   
5. development of alternative treatment strategies other than sequential combination chemotherapy for treatment of HIV infection;
   
   
6. development of a sustained treatment strategy for resource-poor and resource-limited countries;
   
   
7. and preventive HIV vaccine development and evaluation of novel HIV specific immunogens.  In addition to targeted clinical research in the areas noted, our clinical research activity conducts a wide variety of sponsored clinical research in the area of therapeutics for the treatment of HIV, HCV and HPV infection. 

Davis C, Heredia A, Le N, Dominique JK, Redfield RR. Differential Human Immunodeficiency Virus-suppressive Activity of Reverse Transcription Inhibitors in Resting and Activated Peripheral Blood Lymphocytes. JHV. May/June 2001;4(3):113-22.

Heredia A, Davis C, Amoroso A, Dominique JK, Le N, Klingebiel E, Reardon E, Zella D, Redfield RR. Induction of G1 Cell Cycle Arrest in Peripheral Blood Mononuclear Cells Results in Increased Extracellular Levels of RANTES, MIP-18 and MIP-1ß: a Strategy to Inhibit Replication of R5 strains of HIV-1. Proc. Nat'l. Acad. Sci. USA. in press

Heredia A, Margolis D, Oldach D, Hazen R, Nhut L, Redfield R . Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. J AIDS. 1999;22:406-412.

Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, Garner R, Gordin F, Henry D, Holloway W, Kerkering T, Luskin-Hawk R, McNeil J, Michael N, Foster Pierce P, Poretz D, Ratto-Kim S, Renzullo P, Ruiz N, Sitz K, Smith G, Tacket C, Thompson M, Tramont E, Yangco B, Yarrish R, Redfield RR. Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers. rgp160 Phase II Vaccine Investigators. J Infect Dis. 2000; 181:881-9.

Heredia A, Davis C, Redfield RR. Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, Resveratrol. J AIDS. 2000; JAIDS, 2000; 23:246-255.

Back to Primary Faculty

To contact us:

Phone: 410-706-7560
Fax: 410-706-4619
E-mail: kvardjan@ihv.umaryland.edu

Back to Top of Page